High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis.
Shinichiro MiuraHiroshi IwamotoMasashi NambaKakuhiro YamaguchiShinjiro SakamotoYasushi HorimasuTakeshi MasudaShintaro MiyamotoTaku NakashimaShinichiro OhshimoKazunori FujitakaHironobu HamadaNoboru HattoriPublished in: BMJ open respiratory research (2024)
The present results indicate that increased S100A9 expression is associated with IPF progression and that the S100A9 inhibitor paquinimod is a potential treatment for IPF.